The facts
GAAP diluted earnings were US$2.37 per share; adjusted diluted earnings were US$3.82. Both include US$0.11 of acquired research and milestone costs. AP's Zacks survey expected US$3.74 in adjusted earnings per share. [1][3]
Skyrizi and Rinvoq generated US$5.776 billion and US$2.706 billion in quarterly sales, respectively. Humira sales fell 31.2% to US$683 million. [1][2]
Full-year adjusted diluted earnings guidance rose to US$13.95–13.99 per share from US$13.76–13.96. It includes US$0.69 of year-to-date acquired research and milestone costs and excludes such charges arising after the third quarter because they cannot be forecast reliably. [1][2]
The quarterly dividend will increase to US$1.82 per share from US$1.73, payable on 16 February 2027 to shareholders of record on 15 January. [1]
Sources
References support the numbered facts above. Source checks: 30 Oct 2026, 13:26 UTC.
- Third-quarter 2026 financial results
AbbVie · Primary source · 30 Oct 2026
Actual issuer release read, including results, full-year outlook, dividend dates and reconciliation bases. Reported and constant-currency sales, GAAP and adjusted diluted EPS, quarterly and year-to-date acquired-R&D charges remain distinct.
- AbbVie lifts profit forecast as immunology drugs continue to fuel growth
Reuters, via Yahoo News / Kamal Choudhury and Christy Santhosh · Reporting · 30 Oct 2026
Actual current Reuters body read. Reuters is independent of AbbVie and AP. Its analyst comparisons use a different survey from AP/Zacks; this article explicitly uses the named AP/Zacks EPS benchmark without combining the datasets.
- AbbVie: Q3 earnings snapshot
Associated Press / Automated Insights, via The Hour · Reporting · 30 Oct 2026
Actual AP report read. It identifies Automated Insights and Zacks Investment Research as its underlying earnings-data source; this is independent of the issuer and Reuters.